



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Siddhi N. Paudel
✉ paudelsiddhi@gmail.com

RECEIVED 29 June 2024
ACCEPTED 01 July 2024
PUBLISHED 09 July 2024

CITATION

Paudel SN, Hutzen BJ, Miller KE,
Garfinkle EAR, Chen C-Y, Wang P-Y,
Glaspell AM, Currier MA, Ringwalt EM, Boon L,
Mardis ER, Cairo MS, Ratner N, Dodd RD,
Cassady KA and Cripe TP (2024)
Corrigendum: Myelomodulatory treatments
augment the therapeutic benefit of oncolytic
viroimmunotherapy in murine models of
malignant peripheral nerve sheath tumors.
Front. Immunol. 15:1456897.
doi: 10.3389/fimmu.2024.1456897

COPYRIGHT

© 2024 Paudel, Hutzen, Miller, Garfinkle, Chen,
Wang, Glaspell, Currier, Ringwalt, Boon, Mardis,
Cairo, Ratner, Dodd, Cassady and Cripe. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Siddhi N. Paudel^{1*}, Brian J. Hutzen¹, Katherine E. Miller^{2,3},
Elizabeth A. R. Garfinkle², Chun-Yu Chen¹, Pin-Yi Wang¹,
Andrea M. Glaspell¹, Mark A. Currier¹, Emily M. Ringwalt¹,
Louis Boon⁴, Elaine R. Mardis^{2,3}, Mitchell S. Cairo⁵,
Nancy Ratner⁶, Rebecca D. Dodd⁷, Kevin A. Cassady^{1,3}
and Timothy P. Cripe^{1,3,8}

¹Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States, ²Institute for Genomic Medicine, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States, ³Department of Pediatrics, The Ohio State University Wexner College of Medicine, Columbus, OH, United States, ⁴JJP Biologics, Warsaw, Poland, ⁵Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology, and Cell Biology, New York Medical College, Valhalla, NY, United States, ⁶Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, ⁷Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States, ⁸Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH, United States

KEYWORDS

malignant peripheral nerve sheath tumors, immunotherapy, tumor microenvironment, oncolytic virotherapy, macrophage targeting, trabectedin, pexidartinib, T-VEC

A corrigendum on

Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

by Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen C-Y, Wang P-Y, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA and Cripe TP (2024) *Front. Immunol.* 15:1384623. doi: 10.3389/fimmu.2024.1384623

In the published article, there was an error in the legend for Figure 1 as published. We mistakenly referred to the tumor models as xenografts instead of syngeneic models in the sentence: "We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST xenografts."

The corrected legend appears below.

The experimental design used in this report. We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST syngeneic tumors. As none of the

viruses was consistently superior to the others, we chose the FDA-approved virus, T-VEC, to further study in combination with drugs postulated to enable viroimmunotherapy. Because in other studies we found trabectedin to be toxic to C57Bl/6 animals, we pivoted to an MPNST model in the Balb/c background to test that combination.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.